coronavirus vaccine

China’s First Coronavirus Vaccine Delivered for Human Trials

The day after the first clinical trial of a coronavirus vaccine candidate began in the U.S. on March 16, China announced the first clinical trial of its own coronavirus vaccine candidate, called Ad5-nCoV, jointly developed by Cansino Biologics Inc. and the Academy of Military Medical Sciences of China, based on Cansino’s adenovirus-based viral vector vaccine technology platform, which had been successfully used for developing Ebola virus disease vaccine back in 2017. Ad5-nCoV is a recombinant novel coronavirus vaccine, genetically engineered with the replication-defective adenovirus type 5 as a vector to express the spike protein of the novel coronavirus (SARS-CoV-2).